Published in Virology on January 01, 1978
Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol (1994) 4.40
DNA sequence of the viral and cellular src gene of chickens. 1. Complete nucleotide sequence of an EcoRI fragment of recovered avian sarcoma virus which codes for gp37 and pp60src. J Virol (1982) 3.35
Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions. J Virol (1993) 2.80
Structural role of the matrix protein of type D retroviruses in gag polyprotein stability and capsid assembly. J Virol (1990) 2.34
Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein that block processing to gp85 and gp37. J Virol (1987) 2.07
Fine-structure analyses of lipid-protein and protein-protein interactions of gag protein p19 of the avian sarcoma and leukemia viruses by cyanogen bromide mapping. J Virol (1984) 1.90
Isolation and comparative biochemical properties of the major internal polypeptides of equine infectious anemia virus. J Virol (1982) 1.64
Truncated gag-related proteins are produced by large deletion mutants of Rous sarcoma virus and form virus particles. J Virol (1985) 1.63
RNA-binding properties of the matrix protein (p19gag) of avian sarcoma and leukemia viruses. J Virol (1990) 1.59
Murine leukemia virus pol gene products: analysis with antisera generated against reverse transcriptase and endonuclease fusion proteins expressed in Escherichia coli. J Virol (1986) 1.55
Role of conserved gp41 cysteine residues in the processing of human immunodeficiency virus envelope precursor and viral infectivity. J Virol (1991) 1.52
Topography of murine leukemia virus envelope proteins: characterization of transmembrane components. J Virol (1983) 1.45
Cyanogen bromide digestion of the avian myeloblastosis virus pp19 protein: isolation of an amino-terminal peptide that binds to viral RNA. J Virol (1983) 1.27
Extracellular cleavage of the glycoprotein precursor of Rous sarcoma virus. J Virol (1979) 1.14
The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system. J Virol (1999) 1.14
Rosettes from Friend leukemia virus envelope: preparation and physicochemical and partial biological characterization. J Virol (1979) 1.06
Envelope polypeptides of Friend leukemia virus: purification and structural analysis. J Virol (1980) 1.03
Role of gag sequence in the biochemical properties and transforming activity of the avian sarcoma virus UR2-encoded gag-ros fusion protein. J Virol (1990) 0.91
Monoclonal antibodies against baboon endogenous virus and against host cell antigens. J Virol (1982) 0.90
Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41. Retrovirology (2004) 0.89
Expression of endogenous retroviral glycoprotein 70 by antigen-activated cytotoxic and suppressor T lymphocytes of nice. Proc Natl Acad Sci U S A (1982) 0.79
Transformation-defective Rous sarcoma virus mutants with altered p19 of the gag gene and their inhibitory effect on host cell growth. J Virol (1983) 0.75
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A (1988) 7.74
A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses (1989) 7.34
Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci U S A (1989) 6.58
A novel murine oncornavirus with dual eco- and xenotropic properties. Proc Natl Acad Sci U S A (1975) 5.91
Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. Proc Natl Acad Sci U S A (1986) 5.55
A proposed nomenclature for the virion proteins of oncogenic RNA viruses. Virology (1974) 5.01
Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins. J Virol (1995) 4.92
Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A (1986) 4.68
Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science (1990) 4.43
Isolation of an HTLV-III-related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangabeys. Nature (1986) 4.35
Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J Virol (1988) 4.13
Equine infectious anemia virus utilizes a YXXL motif within the late assembly domain of the Gag p9 protein. J Virol (1997) 4.08
Association of viral reverse transcriptase with an enzyme degrading the RNA moiety of RNA-DNA hybrids. Nat New Biol (1971) 3.95
Assembly of type C oncornaviruses: a model. Science (1978) 3.53
Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proc Natl Acad Sci U S A (1987) 3.47
A formalin-inactivated whole SIV vaccine confers protection in macaques. Science (1989) 3.37
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis (1997) 3.35
Lentivirus genomic organization: the complete nucleotide sequence of the env gene region of equine infectious anemia virus. Virology (1986) 3.24
A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol (1995) 3.11
Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A (1997) 3.02
Antigenic variation during persistent infection by equine infectious anemia virus, a retrovirus. J Biol Chem (1984) 3.02
Localization of RNA tumor virus polypeptides. I. Isolation of further virus substructures. Virology (1973) 2.94
Chemotactic peptide receptor modulation in polymorphonuclear leukocytes. J Cell Biol (1980) 2.72
Equine infectious anemia virus Gag polyprotein late domain specifically recruits cellular AP-2 adapter protein complexes during virion assembly. J Virol (1998) 2.68
Sensory adaptation of leukocytes to chemotactic peptides. J Cell Biol (1979) 2.61
Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci U S A (1987) 2.53
Ribonucleic acid components of BAI strain A (myeloblastosis) avian tumor virus. Cancer Res (1967) 2.53
Polypeptides of avian RNA tumor viruses. 1. Isolation and physical and chemical analysis. Virology (1970) 2.49
Rapid emergence of novel antigenic and genetic variants of equine infectious anemia virus during persistent infection. J Virol (1986) 2.42
Isolation of the major viral glycoprotein and a putative precursor from cells transformed by avian sarcoma viruses. Proc Natl Acad Sci U S A (1974) 2.15
Polypeptides of avian RNA tumor viruses. IV. Components of the viral envelope. Virology (1972) 2.09
Reversible staining and peptide mapping of proteins transferred to nitrocellulose after separation by sodium dodecylsulfate-polyacrylamide gel electrophoresis. Anal Biochem (1986) 2.07
Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol (1995) 2.01
The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 2.00
Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J Virol (1997) 2.00
The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles. Biochemistry (2001) 1.88
A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope. Proc Natl Acad Sci U S A (1987) 1.87
Distinct subsets of retroviruses encode dUTPase. J Virol (1992) 1.80
Simian immunodeficiency virus/delta-induced immunodeficiency disease in rhesus monkeys: relation of antibody response and antigenemia. J Infect Dis (1988) 1.75
Neutralization of homologous and heterologous oncornaviruses by antisera against the p15(E) and gp71 polypeptides of Friend murine leukemia virus. Virology (1976) 1.73
Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis (1998) 1.71
Evidence that a precursor glycoprotein is cleaved to yield the major glycoprotein of avian tumor virus. J Virol (1977) 1.70
Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells. Proc Natl Acad Sci U S A (1987) 1.70
Isolation of proteins by gel filtration in 6M guanidinium chloride: application to RNA tumor viruses. Anal Biochem (1974) 1.70
Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol (1990) 1.68
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis (1993) 1.67
Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein. Virology (1993) 1.67
Phenotypic variation in the response to the human immunodeficiency virus among derivatives of the CEM T and WIL-2 B cell lines. J Exp Med (1988) 1.67
CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism. AIDS Res Hum Retroviruses (1993) 1.66
Antigenic variation and lentivirus persistence: variations in envelope gene sequences during EIAV infection resemble changes reported for sequential isolates of HIV. Virology (1987) 1.64
Comparative chemical properties of avian oncornavirus polypeptides. Virology (1975) 1.64
Isolation and comparative biochemical properties of the major internal polypeptides of equine infectious anemia virus. J Virol (1982) 1.64
Polypeptides of mammalian oncornaviruses. II Characterization of murine leukemia virus polypeptide (p 15) bearing interspecies reactivity. Virology (1975) 1.63
Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. J Immunol (1989) 1.63
A structural correlation between lentivirus transmembrane proteins and natural cytolytic peptides. AIDS Res Hum Retroviruses (1991) 1.62
Polypeptides of mammalian oncornaviruses. I. Isolation and serological analysis polypeptides from murine and feline C-type viruses. Virology (1973) 1.59
Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony. J Virol (1997) 1.58
HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. J Immunol (1989) 1.57
Purification and serological characterization of the major envelope glycoprotein from AKR murine leukemia virus and its reactivity with autogenous immune sera from mice. J Virol (1976) 1.56
Expression of murine leukemia virus structural antigens on the surface of chemically induced murine sarcomas. Proc Natl Acad Sci U S A (1974) 1.54
Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain. Virology (2001) 1.52
Asymmetric distribution of the chemotactic peptide receptor on polymorphonuclear leukocytes. J Cell Biol (1984) 1.52
Polypeptides of avian RNA tumor viruses. V. Analysis of the virus core. Virology (1972) 1.51
Replication in vitro and in vivo of an equine infectious anemia virus mutant deficient in dUTPase activity. J Virol (1995) 1.50
Radiolabeling of proteins and viruses in vitro by acetylation with radioactive acetic anhydride. J Biol Chem (1975) 1.49
Characterization of infectious molecular clones of equine infectious anaemia virus. J Gen Virol (1994) 1.49
Polypeptides of mammalian oncornaviruses. III. Localization of p 15 and reactivity with natural antibody. Virology (1975) 1.48
Expression of the Major Viral Glycoprotein of Avian Tumor Virus in Cells of chf(+) Chicken Embryos. J Virol (1975) 1.48
Rapid assay for mycobacterial growth and antibiotic susceptibility using gel microdrop encapsulation. J Clin Microbiol (1995) 1.48
Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. Proc Natl Acad Sci U S A (1987) 1.46
Kinetic analysis of chemotactic peptide receptor modulation. J Cell Biol (1982) 1.45
Virulence and in vitro growth of a cell-adapted strain of equine infectious anemia virus after serial passage in ponies. Am J Vet Res (1982) 1.45
Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. J Virol (1998) 1.43
A general model for the surface glycoproteins of HIV and other retroviruses. AIDS Res Hum Retroviruses (1995) 1.42
Biological, immunological, and biochemical evidence that HIX virus is a recombinant between Moloney leukemia virus and a murine xenotropic C type virus. Virology (1978) 1.42
Macrophage accumulation in mice is inhibited by low molecular weight products from murine leukemia viruses. J Immunol (1980) 1.41
Isolation and characterization of two group-specific antigens from feline leukemia virus. Virology (1971) 1.41
Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies. J Virol (1992) 1.41
Identification of human T cell leukemia virus in a Japanese patient with adult T cell leukemia and cutaneous lymphomatous vasculitis. Proc Natl Acad Sci U S A (1983) 1.41
Observer variation in assessing neurophysical signs among patients with head injuries. Am J Phys Med Rehabil (1991) 1.39
Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals. Lancet (1988) 1.38
Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections. J Virol (1998) 1.38
Structural components of rna tumor viruses. Adv Virus Res (1974) 1.37
Oncogenic and immunogenic potential of cloned HIX virus in mice and cats. Med Microbiol Immunol (1977) 1.37
Equine infectious anemia virus, a putative lentivirus, contains polypeptides analogous to prototype-C oncornaviruses. Virology (1980) 1.36
Novel antimicrobial peptides derived from human immunodeficiency virus type 1 and other lentivirus transmembrane proteins. Antimicrob Agents Chemother (1997) 1.35
Course and extent of variation of equine infectious anemia virus during parallel persistent infections. J Virol (1987) 1.33
Polypeptides of avian RNA tumor viruses. II. Serological characterization. Virology (1970) 1.32
Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J Virol (1992) 1.32
Identification of a calmodulin-binding and inhibitory peptide domain in the HIV-1 transmembrane glycoprotein. AIDS Res Hum Retroviruses (1993) 1.32
Response of bone marrow to MC29 avian leukosis virus in vitro. Cancer Res (1969) 1.30
Polypeptides of mammalian oncornaviruses. IV. Structural components of murine leukemia virus released as soluble antigens in cell culture. Virology (1975) 1.30
GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody. J Immunol (1989) 1.29
Changes in bioactive lipids, alkylacylglycerol and ceramide, occur in HIV-infected cells. Biochem Biophys Res Commun (1992) 1.29
Group-specific antigenic determinants of the large envelope glycoprotein of avian oncornaviruses. Virology (1975) 1.29